The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessAbstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Wong, S. H., & Yu, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0209-8 · Cited by 1,331
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. https://app.cochat.ai/papers/10.1126/science.aar6918
- The paper
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018). The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. https://doi.org/10.1126/science.aar6918
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.